Surgery Enterprise Value Over E B I T D A from 2010 to 2025

SGRY Stock  USD 22.37  0.04  0.18%   
Surgery Partners Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2025. During the period from 2010 to 2025, Surgery Partners Enterprise Value Over EBITDA regression line of annual values had r-squared of  0.14 and arithmetic mean of  17.69. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
12.17371907
Current Value
18.98
Quarterly Volatility
7.30296555
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Surgery Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Surgery Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 78.4 M, Interest Expense of 154.1 M or Selling General Administrative of 86.3 M, as well as many indicators such as Price To Sales Ratio of 1.47, Dividend Yield of 0.0014 or PTB Ratio of 1.57. Surgery financial statements analysis is a perfect complement when working with Surgery Partners Valuation or Volatility modules.
  
Build AI portfolio with Surgery Stock
Check out the analysis of Surgery Partners Correlation against competitors.
For more information on how to buy Surgery Stock please use our How to Invest in Surgery Partners guide.

Latest Surgery Partners' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Surgery Partners over the last few years. It is Surgery Partners' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Surgery Partners' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Surgery Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean17.69
Geometric Mean16.48
Coefficient Of Variation41.28
Mean Deviation5.05
Median18.98
Standard Deviation7.30
Sample Variance53.33
Range25.3068
R-Value(0.38)
Mean Square Error48.88
R-Squared0.14
Significance0.15
Slope(0.58)
Total Sum of Squares800.00

Surgery Enterprise Value Over E B I T D A History

2025 18.98
2024 12.17
2023 15.43
2022 11.32
2021 16.89
2020 15.46
2019 10.59

About Surgery Partners Financial Statements

Surgery Partners investors use historical fundamental indicators, such as Surgery Partners' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Surgery Partners. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 12.17  18.98 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Surgery Stock Analysis

When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.